ERBB2 and gastric cancer: Although lapatinib treatment did not significantly improve survival for HER2-amplified GC patients (TyTAN study), both HER2 amplified (by FISH) and IHC 3+ cases had significantly better progression free survival (HR 0.59, P=0.0176) and overall survival (HR 0.54, P=0.01) [36].